1. Home
  2. PHGE vs CDIO Comparison

PHGE vs CDIO Comparison

Compare PHGE & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$0.20

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

HOLD

Current Price

$1.63

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHGE
CDIO
Founded
2015
2017
Country
United States
United States
Employees
20
17
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
5.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PHGE
CDIO
Price
$0.20
$1.63
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.2M
32.0K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$171,906.75
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.97
52 Week High
$8.50
$7.91

Technical Indicators

Market Signals
Indicator
PHGE
CDIO
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
PHGE
CDIO

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Share on Social Networks: